tiprankstipranks
Advertisement
Advertisement

DE:PHPN Stock Latest News

Buy Rating Reaffirmed on GALT as Belapectin Program De-Risked; $11 Price Target Maintained
RatingsBuy Rating Reaffirmed on GALT as Belapectin Program De-Risked; $11 Price Target Maintained
17d ago
GALT
Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion
PremiumCompany Announcements
Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion
28d ago
8K
GALT
Galectin Therapeutics reaches alignment with FDA on belapectin pathway
PremiumThe Fly
Galectin Therapeutics reaches alignment with FDA on belapectin pathway
2M ago
GALT
Galectin Advances Belapectin to Phase 3 After FDA Alignment
PremiumCompany Announcements
Galectin Advances Belapectin to Phase 3 After FDA Alignment
2M ago
8K
GALT
Galectin Therapeutics presents belapectin data at EASL 2026
PremiumThe Fly
Galectin Therapeutics presents belapectin data at EASL 2026
3M ago
GALT
Galectin Therapeutics publishes NAVIGATE Phase 2b trial results
PremiumThe FlyGalectin Therapeutics publishes NAVIGATE Phase 2b trial results
4M ago
GALT
Galectin Therapeutics files $200M mixed securities shelf
Premium
The Fly
Galectin Therapeutics files $200M mixed securities shelf
5M ago
GALT
Galectin Therapeutics (GALT) (GALT) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Galectin Therapeutics (GALT) (GALT) Q4 Earnings Cheat Sheet
5M ago
GALT
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board
PremiumCompany Announcements
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board
6M ago
8K
GALT
Galectin Therapeutics appoints Henry Brem to board of directors
PremiumThe Fly
Galectin Therapeutics appoints Henry Brem to board of directors
6M ago
GALT
Compelling Risk‑Reward in Galectin Therapeutics: Belapectin’s Differentiated Profile and Biomarker Data Support Buy Rating
PremiumRatings
Compelling Risk‑Reward in Galectin Therapeutics: Belapectin’s Differentiated Profile and Biomarker Data Support Buy Rating
6M ago
GALT
Galectin Therapeutics Approves Retention Bonuses for Key Executives
PremiumCompany Announcements
Galectin Therapeutics Approves Retention Bonuses for Key Executives
7M ago
8K
GALT
Galectin Therapeutics announces board resignation of Marc Rubin
PremiumCompany AnnouncementsGalectin Therapeutics announces board resignation of Marc Rubin
8M ago
8K
GALT
Galectin Advances Belapectin Program, Secures New Insider Financing
Premium
Company Announcements
Galectin Advances Belapectin Program, Secures New Insider Financing
9M ago
8K
GALT
Galectin Therapeutics provides regulatory update following FDA written response
Premium
The Fly
Galectin Therapeutics provides regulatory update following FDA written response
9M ago
GALT
Galectin Therapeutics price target raised to $11 from $6 at H.C. Wainwright
PremiumThe Fly
Galectin Therapeutics price target raised to $11 from $6 at H.C. Wainwright
9M ago
GALT
Galectin Therapeutics Holds 2025 Annual Stockholders Meeting
PremiumCompany Announcements
Galectin Therapeutics Holds 2025 Annual Stockholders Meeting
9M ago
8K
GALT
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
PremiumCompany Announcements
Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
9M ago
8K
GALT
Galectin Therapeutics Reports Q3 2025 Financials
PremiumCompany Announcements
Galectin Therapeutics Reports Q3 2025 Financials
10M ago
GALT
Promising Phase 2 Data Boosts Confidence in Galectin Therapeutics’ Belapectin for Fibrotic Disease Treatment
PremiumRatingsPromising Phase 2 Data Boosts Confidence in Galectin Therapeutics’ Belapectin for Fibrotic Disease Treatment
10M ago
GALT
Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year
Premium
The Fly
Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year
10M ago
GALT
Galectin Therapeutics presents NAVIGATE trial results at AASLD
Premium
The Fly
Galectin Therapeutics presents NAVIGATE trial results at AASLD
10M ago
GALT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >